Biomarkers of oxidative stress and proteopathies in the diagnosis of neurodegenerative diseases
-
Published:2024-04-04
Issue:
Volume:
Page:16-22
-
ISSN:2499-9490
-
Container-title:Molekulyarnaya Meditsina (Molecular medicine)
-
language:
-
Short-container-title:Mol Med Rus
Author:
Mikashinovich Z.I.1, Telesmanich N.R.1, Smirnova O.B.1, Chernogubova E.A.2
Affiliation:
1. Federal State Budgetary Educational Institution of Higher Professional Education «Rostov State Medical University» Ministry of Health of the Russian Federation, Russian Federation, Nakhichevansky per. 29, Rostov-on-Don 2. Federal State Budgetary Institution of Science «Federal Research Center Southern Scientific Center of the Russian Academy of Sciences» of the Ministry of Science and Higher Education of the Russian Federation, Russian Federation, 344006, Rostov-on-Don, Chekhov Ave., 41
Abstract
Introduction. Despite numerous studies in the field of neurodegenerative diseases, the exact mechanisms of these processes have not yet been identified. The purpose of this review is to analyze the methodological approaches necessary to revise the traditional and create new reliable prognostic and diagnostic algorithms that reflect pathogenetic features at different stages of neurodegeneration and atypical course of the disease. Material and methods. The review highlights the results of clinical and experimental studies obtained using a complex of clinical, laboratory and instrumental methods with an emphasis on markers of oxidative stress and proteopathy. In preparing the materials, sources from international and domestic databases were used: Scopus, Web of Science, Pub Medline, RSCI mainly for the last 15 years. Results. An idea has been formed about the molecular mechanisms of neural tissue regression in a number of neurodegenerative diseases such as multiple sclerosis, amyotrophic lateral sclerosis, Alzheimer’s and Parkinson’s disease. The relationship between the parameters of the oxidative process and the features of metal-energy shifts in organs and organ systems is demonstrated. The role of markers of oxidative stress in the early stages, when the process of inflammation prevails and in the atypical course of the disease, is shown. Valuable biochemical markers are cytokines, glutathione levels, myeloperoxidase activation, and isoprostanes. The review points to the prospect of including in screening indicators of iron and other metals such as Zn, Mg, affecting the clinic accumulation of β-amyloid, in connection with which they can be considered as the basis for the progression of neurodegeneration. New data on the contribution of halogenating stress to the pathogenesis of neuroinflammation are presented. An aspect requiring development in the field of biomarkers for assessing the duration of the disease and prognostic prospects is the data on the correlation of metabolic shifts in the intestinal microbiota with the duration of the disease and the inflammatory process. Essential for the creation of express diagnostic methods is the determination of redox balance as an integral marker in saliva, which has obvious advantages over the use of biological fluids, such as liquor and serum. Conclusion. The prospects of creating new prognostic and diagnostic schemes are associated with complexes, including laboratory and instrumental methods, in blood, liquor and saliva. Evaluation of the sensitivity and specificity of new markers depending on the clinical diagnosis allows the selection of pathogenetically significant markers in the early stages of the disease, with atypical neurodegeneration, to establish subtypes of the disease, to carry out their differential diagnosis.
Publisher
Russian Vrach, Publishing House Ltd.
Reference54 articles.
1. Тапахов А.А., Попова Т.Е., Николаева Т.Я., Шнайдер Н.А., Петрова М.М. Эпидемиология болезни Паркинсона в мире и в России. Забайкальский медицинский вестник. 2016; 4: 151–9. [Tapahov A.A., Popova T.E., Nikolaeva T.YA. Shnajder N.A., Petrova M.M. Epidemiology of parkinson’s disease in the world and Russia. Zabajkal’skij medicinskij vestnik. 2016; 4: 151–9 (in Russian)]. 2. Раздорская В.В., Воскресенская О.Н., Юдина Г.К. Болезнь Паркинсона в России: распространенность и заболеваемость (обзор). Саратовский научно-медицинский журнал. 2016; 12 (3): 379–84. [Razdorskaya V.V., Voskresenskaya O.N., Yudina G.K. Parkinson’s disease in Russia: prevalence and incidence (review). Saratovskij nauchno-medicinskij zhurnal. 2016; 12 (3): 379–84 (in Russian)]. 3. Piazza J.R., Almeida D.M., Dmitrieva N.O., Klein L.C. Frontiers in the use of biomarkers of health in research on stress and aging. J. Gerontology: Psychological Sciences. 2010; 65 (5): 513–25. DOI: 10.1093/geronb/gbq049 4. Gao J., Wang L., Liu J., Xie F., Su B., Wang X. Abnormalities of Mitochondrial Dynamics in Neurodegenerative Diseases. Antioxidants (Basel). 2017; 6 (2): 25. DOI: 10.3390/antiox6020025 5. Гапонов Д.О., Пригодина Е.В., Грудина Т.В. Современный взгляд на патогенетические механизмы прогрессирования болезни Паркинсона. РМЖ. 2018; 26 (12–1): 66–72. [Gaponov D.O., Prigodina E.V., Grudina T.V. Modern view on the pathogenetic mechanisms of Parkinson’s disease progression. RMZH. 2018; 26 (12–1): 66–72 (in Russian)].
|
|